The abstract is read at the publisher; the summary is JClub's.
A novel heterozygous MYBPC1 M-motif variant, c.779G>A p (Arg260His), is linked to CMYO16 in four family members, and oral pyridostigmine showed apparent benefit.
- Why it matters: CMYO16 is a mild, early-onset, slowly progressive congenital myopathy with tremor, yet no disease-specific or symptom-directed pharmacologic therapy has been described.
- What they did: In a multigenerational family, pyridostigmine was trialed in the proband at 16 months using a blinded one-week-on/one-week-off assessment, with caregiver and adult self-reports.
- The result: Across three generations (ages 2–65 years), caregivers and three affected adults reported improved stamina and reduced tremors, suggesting a possible pyridostigmine response in MYBPC1-associated congenital myopathy with tremor.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.